Unmasking the common enemy: drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling
Yu Zhang·Jakub Hofman·Rudolf Kupčík·Youssif Budagaga·Dimitrios Vagiannis·Ziba Sabet·Kaisa Lehti·Okan Gültekin
Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits. However, acquired resistance remains a significant obstacle, undermining long-term efficacy. While specific mechanisms of EGFR-TKI resistance have been reported, potential shared mechanisms across EGFR-TKI generations have remained unclear. Methods Drug-resistant HCC827 and NCI-H1975 cells were developed